menu
    • menu
    [{"orgOrder":0,"company":"Kyongbo Pharmaceutical Co., Ltd","sponsor":"Kyongbo Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase IV","graph3":"Kyongbo Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Kyongbo Pharmaceutical Co., Ltd","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kyongbo Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Kyongbo Pharmaceutical Co., Ltd","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kyongbo Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Kyongbo Pharmaceutical Co., Ltd

    Menu

    Kyongbo Pharmaceutical Co., Ltd

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kyongbo Pharmaceutical Co., Ltd

                            South Korea arrow
                            Pharma MES 2025
                            Not Confirmed

                            Kyongbo Pharmaceutical Co., Ltd

                            South Korea arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Phase IV

                            Recipient : Korea University Guro Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Impact of Maxigesic on Delirium After Minimally Invasive Lung Surgery in Elderly Patients

                            Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Delirium.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 28, 2023

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase IV

                            Recipient : Korea University Guro Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kyongbo Pharmaceutical Co., Ltd

                            South Korea arrow
                            Pharma MES 2025
                            Not Confirmed

                            Kyongbo Pharmaceutical Co., Ltd

                            South Korea arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Preemptive and Preventive Acetaminophen/Ibuprofen Fixed-dose Combination After Robot-assisted Radical Prostate...

                            Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Pain, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 17, 2023

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kyongbo Pharmaceutical Co., Ltd

                            South Korea arrow
                            Pharma MES 2025
                            Not Confirmed

                            Kyongbo Pharmaceutical Co., Ltd

                            South Korea arrow
                            Pharma MES 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Study Phase : Undisclosed

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Intravenous Acetaminophen/Ibuprofen Fixed-dose Combination on Postoperative Opioid Consumption

                            Details : Acetaminophen is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Pain, Postoperative.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 09, 2022

                            Lead Product(s) : Paracetamol

                            Therapeutic Area : Neurology

                            Highest Development Status : Undisclosed

                            Recipient : Seoul National University Hospital

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth